APO Research
Talk to an analyst

APO RESEARCH · REPORT

Cancer Radioimmunotherapy

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Cancer Radioimmunotherapy Market Outlook and Growth Opportunities 2026

29 December 2025201 pages

Choose your research edition.

Industry ResearchCancer Radioimmunotherapy Industry Research Report 2026127 pages · $2,950 USDIndustry Growth & TrendsGlobal Cancer Radioimmunotherapy Industry Growth and Trends Forecast to 2032110 pages · $3,450 USDMarket StructureGlobal Cancer Radioimmunotherapy Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032193 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Cancer Radioimmunotherapy Market Outlook and Growth Opportunities 2026201 pages · $4,250 USDMarket Analysis & ForecastGlobal Cancer Radioimmunotherapy Market Analysis and Forecast 2026-2032208 pages · $4,950 USD

Market perspective

The global Cancer Radioimmunotherapy market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Cancer Radioimmunotherapy is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Cancer Radioimmunotherapy is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Cancer Radioimmunotherapy is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Cancer Radioimmunotherapy market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Cancer Radioimmunotherapy market include Novartis, Bayer, Y-mAbs Therapeutics, Telix Pharmaceuticals, RadioMedix, Philogen, Orano Med, Nordic Nanovector and Mundipharma, among others. In 2025, the top three vendors together accounted for approximately % of global market revenue.

This report provides an overview of the global Cancer Radioimmunotherapy market in terms of revenue and gross margin, analyzing global market trends using historical revenue data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Cancer Radioimmunotherapy and market revenue by major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Cancer Radioimmunotherapy revenue, market share, and industry ranking for the main companies for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

Across the 2021-2026 period, the analysis compares revenue growth and profitability profiles by company, distinguishing participants with sustained expansion from those with more cyclical performance, and relates these patterns to differences in regional exposure, product portfolios, and application focus in the global Cancer Radioimmunotherapy market.

Cancer Radioimmunotherapy Segment by Company

Novartis

Bayer

Y-mAbs Therapeutics

Telix Pharmaceuticals

RadioMedix

Philogen

Orano Med

Nordic Nanovector

Mundipharma

Lantheus

Gilead Sciences

Fusion Pharmaceuticals

Curium Pharmaceuticals

Curasight

Clarity Pharmaceuticals

China Isotope & Radiation

Aurobindo Pharma

Actinium Pharmaceuticals

Cancer Radioimmunotherapy Segment by Type

Beta-emitting

Targeted Alpha Therapy

Cancer Radioimmunotherapy Segment by Application

Solid Tumor

Non Hodgkin Lymphoma

Cancer Radioimmunotherapy Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global Cancer Radioimmunotherapy status and future forecast, involving, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the Cancer Radioimmunotherapy key companies, revenue, market share, and recent developments.

3. To split the Cancer Radioimmunotherapy breakdown data by regions, type, companies, and application.

4. To analyze the global and key regions Cancer Radioimmunotherapy market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Cancer Radioimmunotherapy significant trends, drivers, influence factors in global and regions.

6. To analyze Cancer Radioimmunotherapy competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Cancer Radioimmunotherapy market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Cancer Radioimmunotherapy and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Cancer Radioimmunotherapy.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, global total market size.

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Cancer Radioimmunotherapy industry.

Chapter 3: Detailed analysis of Cancer Radioimmunotherapy company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales value of Cancer Radioimmunotherapy in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of key country in the world.

Chapter 7: Sales value of Cancer Radioimmunotherapy in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.

Chapter 9: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Cancer Radioimmunotherapy Industry Trends Table 2. Cancer Radioimmunotherapy Industry Drivers Table 3. Cancer Radioimmunotherapy Industry Opportunities and Challenges Table 4. Cancer Radioimmunotherapy Industry Restraints Table 5. Global Cancer Radioimmunotherapy Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Cancer Radioimmunotherapy Revenue Share by Company (2021-2026) Table 7. Global Cancer Radioimmunotherapy Company Ranking, (2024-2026) & (US$ Million) Table 8. Global Cancer Radioimmunotherapy Key Company Manufacturing Base & Headquarters Table 9. Global Cancer Radioimmunotherapy Company, Product Type & Application Table 10. Global Cancer Radioimmunotherapy Company Establishment Date Table 11. Global Company Market Concentration Ratio (CR5 and HHI) Table 12. Global Cancer Radioimmunotherapy by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 13. Mergers & Acquisitions, Expansion Table 14. Significant Companies of Beta-emitting Table 15. Significant Companies of Targeted Alpha Therapy Table 16. Global Cancer Radioimmunotherapy Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 17. Global Cancer Radioimmunotherapy Sales Value by Type (2021-2026) & (US$ Million) Table 18. Global Cancer Radioimmunotherapy Sales Value by Type (2027-2032) & (US$ Million) Table 19. Global Cancer Radioimmunotherapy Sales Value Share by Type (2021-2026) Table 20. Global Cancer Radioimmunotherapy Sales Value Share by Type (2027-2032) Table 21. Significant Companies of Solid Tumor Table 22. Significant Companies of Non Hodgkin Lymphoma Table 23. Global Cancer Radioimmunotherapy Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 24. Global Cancer Radioimmunotherapy Sales Value by Application (2021-2026) & (US$ Million) Table 25. Global Cancer Radioimmunotherapy Sales Value by Application (2027-2032) & (US$ Million) Table 26. Global Cancer Radioimmunotherapy Sales Value Share by Application (2021-2026) Table 27. Global Cancer Radioimmunotherapy Sales Value Share by Application (2027-2032) Table 28. Global Cancer Radioimmunotherapy Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 29. Global Cancer Radioimmunotherapy Sales Value by Region (2021-2026) & (US$ Million) Table 30. Global Cancer Radioimmunotherapy Sales Value Share by Region (2021-2026) Table 31. Global Cancer Radioimmunotherapy Sales Value by Region (2027-2032) & (US$ Million) Table 32. Global Cancer Radioimmunotherapy Sales Value Share by Region (2027-2032) Table 33. Global Cancer Radioimmunotherapy Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 34. Global Cancer Radioimmunotherapy Sales Value by Country (2021-2026) & (US$ Million) Table 35. Global Cancer Radioimmunotherapy Sales Value Market Share by Country (2021-2026) Table 36. Global Cancer Radioimmunotherapy Sales Value by Country (2027-2032) & (US$ Million) Table 37. Global Cancer Radioimmunotherapy Sales Value Market Share by Country (2027-2032) Table 38. Novartis Company Information Table 39. Novartis Business Overview Table 40. Novartis Cancer Radioimmunotherapy Revenue (US$ Million) and Gross Margin (2021-2026) Table 41. Novartis Cancer Radioimmunotherapy Product Portfolio Table 42. Novartis Recent Development Table 43. Bayer Company Information Table 44. Bayer Business Overview Table 45. Bayer Cancer Radioimmunotherapy Revenue (US$ Million) and Gross Margin (2021-2026) Table 46. Bayer Cancer Radioimmunotherapy Product Portfolio Table 47. Bayer Recent Development Table 48. Y-mAbs Therapeutics Company Information Table 49. Y-mAbs Therapeutics Business Overview Table 50. Y-mAbs Therapeutics Cancer Radioimmunotherapy Revenue (US$ Million) and Gross Margin (2021-2026) Table 51. Y-mAbs Therapeutics Cancer Radioimmunotherapy Product Portfolio Table 52. Y-mAbs Therapeutics Recent Development Table 53. Telix Pharmaceuticals Company Information Table 54. Telix Pharmaceuticals Business Overview Table 55. Telix Pharmaceuticals Cancer Radioimmunotherapy Revenue (US$ Million) and Gross Margin (2021-2026) Table 56. Telix Pharmaceuticals Cancer Radioimmunotherapy Product Portfolio Table 57. Telix Pharmaceuticals Recent Development Table 58. RadioMedix Company Information Table 59. RadioMedix Business Overview Table 60. RadioMedix Cancer Radioimmunotherapy Revenue (US$ Million) and Gross Margin (2021-2026) Table 61. RadioMedix Cancer Radioimmunotherapy Product Portfolio Table 62. RadioMedix Recent Development Table 63. Philogen Company Information Table 64. Philogen Business Overview Table 65. Philogen Cancer Radioimmunotherapy Revenue (US$ Million) and Gross Margin (2021-2026) Table 66. Philogen Cancer Radioimmunotherapy Product Portfolio Table 67. Philogen Recent Development Table 68. Orano Med Company Information Table 69. Orano Med Business Overview Table 70. Orano Med Cancer Radioimmunotherapy Revenue (US$ Million) and Gross Margin (2021-2026) Table 71. Orano Med Cancer Radioimmunotherapy Product Portfolio Table 72. Orano Med Recent Development Table 73. Nordic Nanovector Company Information Table 74. Nordic Nanovector Business Overview Table 75. Nordic Nanovector Cancer Radioimmunotherapy Revenue (US$ Million) and Gross Margin (2021-2026) Table 76. Nordic Nanovector Cancer Radioimmunotherapy Product Portfolio Table 77. Nordic Nanovector Recent Development Table 78. Mundipharma Company Information Table 79. Mundipharma Business Overview Table 80. Mundipharma Cancer Radioimmunotherapy Revenue (US$ Million) and Gross Margin (2021-2026) Table 81. Mundipharma Cancer Radioimmunotherapy Product Portfolio Table 82. Mundipharma Recent Development Table 83. Lantheus Company Information Table 84. Lantheus Business Overview Table 85. Lantheus Cancer Radioimmunotherapy Revenue (US$ Million) and Gross Margin (2021-2026) Table 86. Lantheus Cancer Radioimmunotherapy Product Portfolio Table 87. Lantheus Recent Development Table 88. Gilead Sciences Company Information Table 89. Gilead Sciences Business Overview Table 90. Gilead Sciences Cancer Radioimmunotherapy Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 91. Gilead Sciences Cancer Radioimmunotherapy Product Portfolio Table 92. Gilead Sciences Recent Development Table 93. Fusion Pharmaceuticals Company Information Table 94. Fusion Pharmaceuticals Business Overview Table 95. Fusion Pharmaceuticals Cancer Radioimmunotherapy Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 96. Fusion Pharmaceuticals Cancer Radioimmunotherapy Product Portfolio Table 97. Fusion Pharmaceuticals Recent Development Table 98. Curium Pharmaceuticals Company Information Table 99. Curium Pharmaceuticals Business Overview Table 100. Curium Pharmaceuticals Cancer Radioimmunotherapy Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 101. Curium Pharmaceuticals Cancer Radioimmunotherapy Product Portfolio Table 102. Curium Pharmaceuticals Recent Development Table 103. Curasight Company Information Table 104. Curasight Business Overview Table 105. Curasight Cancer Radioimmunotherapy Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 106. Curasight Cancer Radioimmunotherapy Product Portfolio Table 107. Curasight Recent Development Table 108. Clarity Pharmaceuticals Company Information Table 109. Clarity Pharmaceuticals Business Overview Table 110. Clarity Pharmaceuticals Cancer Radioimmunotherapy Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 111. Clarity Pharmaceuticals Cancer Radioimmunotherapy Product Portfolio Table 112. Clarity Pharmaceuticals Recent Development Table 113. China Isotope & Radiation Company Information Table 114. China Isotope & Radiation Business Overview Table 115. China Isotope & Radiation Cancer Radioimmunotherapy Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 116. China Isotope & Radiation Cancer Radioimmunotherapy Product Portfolio Table 117. China Isotope & Radiation Recent Development Table 118. Aurobindo Pharma Company Information Table 119. Aurobindo Pharma Business Overview Table 120. Aurobindo Pharma Cancer Radioimmunotherapy Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 121. Aurobindo Pharma Cancer Radioimmunotherapy Product Portfolio Table 122. Aurobindo Pharma Recent Development Table 123. Actinium Pharmaceuticals Company Information Table 124. Actinium Pharmaceuticals Business Overview Table 125. Actinium Pharmaceuticals Cancer Radioimmunotherapy Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 126. Actinium Pharmaceuticals Cancer Radioimmunotherapy Product Portfolio Table 127. Actinium Pharmaceuticals Recent Development Table 128. Research Programs/Design for This Report Table 129. Authors List of This Report Table 130. Secondary Sources Table 131. Primary Sources List of Figures Figure 1. Cancer Radioimmunotherapy Product Image Figure 2. Global Cancer Radioimmunotherapy Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Cancer Radioimmunotherapy Market Size (2021-2032) & (US$ Million) Figure 4. Global Cancer Radioimmunotherapy Company Revenue Ranking in 2025 (US$ Million) Figure 5. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 6. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 7. Beta-emitting Image Figure 8. Targeted Alpha Therapy Image Figure 9. Global Cancer Radioimmunotherapy Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 10. Global Cancer Radioimmunotherapy Sales Value Share 2021 VS 2025 VS 2032 Figure 11. Global Cancer Radioimmunotherapy Sales Value Share by Type (2021-2032) Figure 12. Solid Tumor Image Figure 13. Non Hodgkin Lymphoma Image Figure 14. Global Cancer Radioimmunotherapy Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 15. Global Cancer Radioimmunotherapy Sales Value Share 2021 VS 2025 VS 2032 Figure 16. Global Cancer Radioimmunotherapy Sales Value Share by Application (2021-2032) Figure 17. Global Cancer Radioimmunotherapy Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 18. Global Cancer Radioimmunotherapy Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 19. North America Cancer Radioimmunotherapy Sales Value (2021-2032) & (US$ Million) Figure 20. North America Cancer Radioimmunotherapy Sales Value Share by Country (%), 2025 VS 2032 Figure 21. Europe Cancer Radioimmunotherapy Sales Value (2021-2032) & (US$ Million) Figure 22. Europe Cancer Radioimmunotherapy Sales Value Share by Country (%), 2025 VS 2032 Figure 23. Asia-Pacific Cancer Radioimmunotherapy Sales Value (2021-2032) & (US$ Million) Figure 24. Asia-Pacific Cancer Radioimmunotherapy Sales Value Share by Country (%), 2025 VS 2032 Figure 25. South America Cancer Radioimmunotherapy Sales Value (2021-2032) & (US$ Million) Figure 26. South America Cancer Radioimmunotherapy Sales Value Share by Country (%), 2025 VS 2032 Figure 27. Middle East & Africa Cancer Radioimmunotherapy Sales Value (2021-2032) & (US$ Million) Figure 28. Middle East & Africa Cancer Radioimmunotherapy Sales Value Share by Country (%), 2025 VS 2032 Figure 29. USA Cancer Radioimmunotherapy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 30. USA Cancer Radioimmunotherapy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 31. USA Cancer Radioimmunotherapy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 32. Canada Cancer Radioimmunotherapy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 33. Canada Cancer Radioimmunotherapy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 34. Canada Cancer Radioimmunotherapy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 35. Mexico Cancer Radioimmunotherapy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 36. Mexico Cancer Radioimmunotherapy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 37. Mexico Cancer Radioimmunotherapy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 38. Germany Cancer Radioimmunotherapy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 39. Germany Cancer Radioimmunotherapy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 40. Germany Cancer Radioimmunotherapy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 41. France Cancer Radioimmunotherapy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 42. France Cancer Radioimmunotherapy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 43. France Cancer Radioimmunotherapy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 44. U.K. Cancer Radioimmunotherapy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 45. U.K. Cancer Radioimmunotherapy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 46. U.K. Cancer Radioimmunotherapy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 47. Italy Cancer Radioimmunotherapy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 48. Italy Cancer Radioimmunotherapy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 49. Italy Cancer Radioimmunotherapy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 50. Spain Cancer Radioimmunotherapy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 51. Spain Cancer Radioimmunotherapy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 52. Spain Cancer Radioimmunotherapy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 53. Russia Cancer Radioimmunotherapy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 54. Russia Cancer Radioimmunotherapy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 55. Russia Cancer Radioimmunotherapy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 56. Netherlands Cancer Radioimmunotherapy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 57. Netherlands Cancer Radioimmunotherapy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 58. Netherlands Cancer Radioimmunotherapy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 59. Nordic Countries Cancer Radioimmunotherapy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 60. Nordic Countries Cancer Radioimmunotherapy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 61. Nordic Countries Cancer Radioimmunotherapy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 62. China Cancer Radioimmunotherapy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 63. China Cancer Radioimmunotherapy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 64. China Cancer Radioimmunotherapy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 65. Japan Cancer Radioimmunotherapy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 66. Japan Cancer Radioimmunotherapy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 67. Japan Cancer Radioimmunotherapy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 68. South Korea Cancer Radioimmunotherapy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 69. South Korea Cancer Radioimmunotherapy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 70. South Korea Cancer Radioimmunotherapy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 71. India Cancer Radioimmunotherapy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 72. India Cancer Radioimmunotherapy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 73. India Cancer Radioimmunotherapy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 74. Australia Cancer Radioimmunotherapy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 75. Australia Cancer Radioimmunotherapy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 76. Australia Cancer Radioimmunotherapy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 77. Southeast Asia Cancer Radioimmunotherapy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 78. Southeast Asia Cancer Radioimmunotherapy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 79. Southeast Asia Cancer Radioimmunotherapy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 80. Brazil Cancer Radioimmunotherapy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 81. Brazil Cancer Radioimmunotherapy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 82. Brazil Cancer Radioimmunotherapy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 83. Argentina Cancer Radioimmunotherapy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 84. Argentina Cancer Radioimmunotherapy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 85. Argentina Cancer Radioimmunotherapy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 86. Chile Cancer Radioimmunotherapy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 87. Chile Cancer Radioimmunotherapy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 88. Chile Cancer Radioimmunotherapy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 89. Colombia Cancer Radioimmunotherapy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 90. Colombia Cancer Radioimmunotherapy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 91. Colombia Cancer Radioimmunotherapy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 92. Peru Cancer Radioimmunotherapy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 93. Peru Cancer Radioimmunotherapy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 94. Peru Cancer Radioimmunotherapy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 95. Saudi Arabia Cancer Radioimmunotherapy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 96. Saudi Arabia Cancer Radioimmunotherapy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 97. Saudi Arabia Cancer Radioimmunotherapy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 98. Israel Cancer Radioimmunotherapy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 99. Israel Cancer Radioimmunotherapy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 100. Israel Cancer Radioimmunotherapy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 101. UAE Cancer Radioimmunotherapy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 102. UAE Cancer Radioimmunotherapy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 103. UAE Cancer Radioimmunotherapy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 104. Turkey Cancer Radioimmunotherapy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 105. Turkey Cancer Radioimmunotherapy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 106. Turkey Cancer Radioimmunotherapy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 107. Iran Cancer Radioimmunotherapy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 108. Iran Cancer Radioimmunotherapy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 109. Iran Cancer Radioimmunotherapy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 110. Egypt Cancer Radioimmunotherapy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 111. Egypt Cancer Radioimmunotherapy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 112. Egypt Cancer Radioimmunotherapy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 113. Years Considered Figure 114. Research Process Figure 115. Key Executives Interviewed

Scope & coverage.

Types
  • Beta-emitting
  • Targeted Alpha Therapy
Applications
  • Solid Tumor
  • Non Hodgkin Lymphoma
Companies covered
  • Novartis
  • Bayer
  • Y-mAbs Therapeutics
  • Telix Pharmaceuticals
  • RadioMedix
  • Philogen
  • Orano Med
  • Nordic Nanovector
  • Mundipharma
  • Lantheus
  • Gilead Sciences
  • Fusion Pharmaceuticals
  • Curium Pharmaceuticals
  • Curasight
  • Clarity Pharmaceuticals
  • China Isotope & Radiation
  • Aurobindo Pharma
  • Actinium Pharmaceuticals

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Cancer Radioimmunotherapy Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Cancer Radioimmunotherapy Market Size (2021-2032)
  4. 1.4 Assumptions and Limitations
  5. 1.5 Study Goals and Objectives
2 Cancer Radioimmunotherapy Market Dynamics
  1. 2.1 Cancer Radioimmunotherapy Industry Trends
  2. 2.2 Cancer Radioimmunotherapy Industry Drivers
  3. 2.3 Cancer Radioimmunotherapy Industry Opportunities and Challenges
  4. 2.4 Cancer Radioimmunotherapy Industry Restraints
3 Cancer Radioimmunotherapy Market by Company
  1. 3.1 Global Cancer Radioimmunotherapy Company Revenue Ranking in 2025
  2. 3.2 Global Cancer Radioimmunotherapy Revenue by Company (2021-2026)
  3. 3.3 Global Cancer Radioimmunotherapy Company Ranking (2024-2026)
  4. 3.4 Global Cancer Radioimmunotherapy Company Manufacturing Base and Headquarters
  5. 3.5 Global Cancer Radioimmunotherapy Company Product Type and Application
  6. 3.6 Global Cancer Radioimmunotherapy Company Establishment Date
  7. 3.7 Market Competitive Analysis
  8. 3.7.1 Global Cancer Radioimmunotherapy Market Concentration Ratio (CR5 and HHI)
  9. 3.7.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  10. 3.7.3 2025 Cancer Radioimmunotherapy Tier 1, Tier 2, and Tier 3 Companies
  11. 3.8 Mergers and Acquisitions Expansion
4 Cancer Radioimmunotherapy Market by Type
  1. 4.1 Cancer Radioimmunotherapy Type Introduction
  2. 4.1.1 Beta-emitting
  3. 4.1.2 Targeted Alpha Therapy
  4. 4.2 Global Cancer Radioimmunotherapy Sales Value by Type
  5. 4.2.1 Global Cancer Radioimmunotherapy Sales Value by Type (2021 VS 2025 VS 2032)
  6. 4.2.2 Global Cancer Radioimmunotherapy Sales Value by Type (2021-2032)
  7. 4.2.3 Global Cancer Radioimmunotherapy Sales Value Share by Type (2021-2032)
5 Cancer Radioimmunotherapy Market by Application
  1. 5.1 Cancer Radioimmunotherapy Application Introduction
  2. 5.1.1 Solid Tumor
  3. 5.1.2 Non Hodgkin Lymphoma
  4. 5.2 Global Cancer Radioimmunotherapy Sales Value by Application
  5. 5.2.1 Global Cancer Radioimmunotherapy Sales Value by Application (2021 VS 2025 VS 2032)
  6. 5.2.2 Global Cancer Radioimmunotherapy Sales Value by Application (2021-2032)
  7. 5.2.3 Global Cancer Radioimmunotherapy Sales Value Share by Application (2021-2032)
6 Cancer Radioimmunotherapy Regional Value Analysis
  1. 6.1 Global Cancer Radioimmunotherapy Sales Value by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Cancer Radioimmunotherapy Sales Value by Region (2021-2032)
  3. 6.2.1 Global Cancer Radioimmunotherapy Sales Value by Region: 2021-2026
  4. 6.2.2 Global Cancer Radioimmunotherapy Sales Value by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Cancer Radioimmunotherapy Sales Value (2021-2032)
  7. 6.3.2 North America Cancer Radioimmunotherapy Sales Value Share by Country, 2025 VS 2032
  8. 6.4 Europe
  9. 6.4.1 Europe Cancer Radioimmunotherapy Sales Value (2021-2032)
  10. 6.4.2 Europe Cancer Radioimmunotherapy Sales Value Share by Country, 2025 VS 2032
  11. 6.5 Asia-Pacific
  12. 6.5.1 Asia-Pacific Cancer Radioimmunotherapy Sales Value (2021-2032)
  13. 6.5.2 Asia-Pacific Cancer Radioimmunotherapy Sales Value Share by Country, 2025 VS 2032
  14. 6.6 South America
  15. 6.6.1 South America Cancer Radioimmunotherapy Sales Value (2021-2032)
  16. 6.6.2 South America Cancer Radioimmunotherapy Sales Value Share by Country, 2025 VS 2032
  17. 6.7 Middle East & Africa
  18. 6.7.1 Middle East & Africa Cancer Radioimmunotherapy Sales Value (2021-2032)
  19. 6.7.2 Middle East & Africa Cancer Radioimmunotherapy Sales Value Share by Country, 2025 VS 2032
7 Cancer Radioimmunotherapy Country-level Value Analysis
  1. 7.1 Global Cancer Radioimmunotherapy Sales Value by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Cancer Radioimmunotherapy Sales Value by Country (2021-2032)
  3. 7.2.1 Global Cancer Radioimmunotherapy Sales Value by Country (2021-2026)
  4. 7.2.2 Global Cancer Radioimmunotherapy Sales Value by Country (2027-2032)
  5. 7.3 USA
  6. 7.3.1 USA Cancer Radioimmunotherapy Sales Value Growth Rate (2021-2032)
  7. 7.3.2 USA Cancer Radioimmunotherapy Sales Value Share by Type, 2025 VS 2032
  8. 7.3.3 USA Cancer Radioimmunotherapy Sales Value Share by Application, 2025 VS 2032
  9. 7.4 Canada
  10. 7.4.1 Canada Cancer Radioimmunotherapy Sales Value Growth Rate (2021-2032)
  11. 7.4.2 Canada Cancer Radioimmunotherapy Sales Value Share by Type, 2025 VS 2032
  12. 7.4.3 Canada Cancer Radioimmunotherapy Sales Value Share by Application, 2025 VS 2032
  13. 7.5 Mexico
  14. 7.5.1 Mexico Cancer Radioimmunotherapy Sales Value Growth Rate (2021-2032)
  15. 7.5.2 Mexico Cancer Radioimmunotherapy Sales Value Share by Type, 2025 VS 2032
  16. 7.5.3 Mexico Cancer Radioimmunotherapy Sales Value Share by Application, 2025 VS 2032
  17. 7.6 Germany
  18. 7.6.1 Germany Cancer Radioimmunotherapy Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Germany Cancer Radioimmunotherapy Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Germany Cancer Radioimmunotherapy Sales Value Share by Application, 2025 VS 2032
  21. 7.7 France
  22. 7.7.1 France Cancer Radioimmunotherapy Sales Value Growth Rate (2021-2032)
  23. 7.7.2 France Cancer Radioimmunotherapy Sales Value Share by Type, 2025 VS 2032
  24. 7.7.3 France Cancer Radioimmunotherapy Sales Value Share by Application, 2025 VS 2032
  25. 7.8 U.K.
  26. 7.8.1 U.K. Cancer Radioimmunotherapy Sales Value Growth Rate (2021-2032)
  27. 7.8.2 U.K. Cancer Radioimmunotherapy Sales Value Share by Type, 2025 VS 2032
  28. 7.8.3 U.K. Cancer Radioimmunotherapy Sales Value Share by Application, 2025 VS 2032
  29. 7.9 Italy
  30. 7.9.1 Italy Cancer Radioimmunotherapy Sales Value Growth Rate (2021-2032)
  31. 7.9.2 Italy Cancer Radioimmunotherapy Sales Value Share by Type, 2025 VS 2032
  32. 7.9.3 Italy Cancer Radioimmunotherapy Sales Value Share by Application, 2025 VS 2032
  33. 7.10 Spain
  34. 7.10.1 Spain Cancer Radioimmunotherapy Sales Value Growth Rate (2021-2032)
  35. 7.10.2 Spain Cancer Radioimmunotherapy Sales Value Share by Type, 2025 VS 2032
  36. 7.10.3 Spain Cancer Radioimmunotherapy Sales Value Share by Application, 2025 VS 2032
  37. 7.11 Russia
  38. 7.11.1 Russia Cancer Radioimmunotherapy Sales Value Growth Rate (2021-2032)
  39. 7.11.2 Russia Cancer Radioimmunotherapy Sales Value Share by Type, 2025 VS 2032
  40. 7.11.3 Russia Cancer Radioimmunotherapy Sales Value Share by Application, 2025 VS 2032
  41. 7.12 Netherlands
  42. 7.12.1 Netherlands Cancer Radioimmunotherapy Sales Value Growth Rate (2021-2032)
  43. 7.12.2 Netherlands Cancer Radioimmunotherapy Sales Value Share by Type, 2025 VS 2032
  44. 7.12.3 Netherlands Cancer Radioimmunotherapy Sales Value Share by Application, 2025 VS 2032
  45. 7.13 Nordic Countries
  46. 7.13.1 Nordic Countries Cancer Radioimmunotherapy Sales Value Growth Rate (2021-2032)
  47. 7.13.2 Nordic Countries Cancer Radioimmunotherapy Sales Value Share by Type, 2025 VS 2032
  48. 7.13.3 Nordic Countries Cancer Radioimmunotherapy Sales Value Share by Application, 2025 VS 2032
  49. 7.14 China
  50. 7.14.1 China Cancer Radioimmunotherapy Sales Value Growth Rate (2021-2032)
  51. 7.14.2 China Cancer Radioimmunotherapy Sales Value Share by Type, 2025 VS 2032
  52. 7.14.3 China Cancer Radioimmunotherapy Sales Value Share by Application, 2025 VS 2032
  53. 7.15 Japan
  54. 7.15.1 Japan Cancer Radioimmunotherapy Sales Value Growth Rate (2021-2032)
  55. 7.15.2 Japan Cancer Radioimmunotherapy Sales Value Share by Type, 2025 VS 2032
  56. 7.15.3 Japan Cancer Radioimmunotherapy Sales Value Share by Application, 2025 VS 2032
  57. 7.16 South Korea
  58. 7.16.1 South Korea Cancer Radioimmunotherapy Sales Value Growth Rate (2021-2032)
  59. 7.16.2 South Korea Cancer Radioimmunotherapy Sales Value Share by Type, 2025 VS 2032
  60. 7.16.3 South Korea Cancer Radioimmunotherapy Sales Value Share by Application, 2025 VS 2032
  61. 7.17 India
  62. 7.17.1 India Cancer Radioimmunotherapy Sales Value Growth Rate (2021-2032)
  63. 7.17.2 India Cancer Radioimmunotherapy Sales Value Share by Type, 2025 VS 2032
  64. 7.17.3 India Cancer Radioimmunotherapy Sales Value Share by Application, 2025 VS 2032
  65. 7.18 Australia
  66. 7.18.1 Australia Cancer Radioimmunotherapy Sales Value Growth Rate (2021-2032)
  67. 7.18.2 Australia Cancer Radioimmunotherapy Sales Value Share by Type, 2025 VS 2032
  68. 7.18.3 Australia Cancer Radioimmunotherapy Sales Value Share by Application, 2025 VS 2032
  69. 7.19 Southeast Asia
  70. 7.19.1 Southeast Asia Cancer Radioimmunotherapy Sales Value Growth Rate (2021-2032)
  71. 7.19.2 Southeast Asia Cancer Radioimmunotherapy Sales Value Share by Type, 2025 VS 2032
  72. 7.19.3 Southeast Asia Cancer Radioimmunotherapy Sales Value Share by Application, 2025 VS 2032
  73. 7.20 Brazil
  74. 7.20.1 Brazil Cancer Radioimmunotherapy Sales Value Growth Rate (2021-2032)
  75. 7.20.2 Brazil Cancer Radioimmunotherapy Sales Value Share by Type, 2025 VS 2032
  76. 7.20.3 Brazil Cancer Radioimmunotherapy Sales Value Share by Application, 2025 VS 2032
  77. 7.21 Argentina
  78. 7.21.1 Argentina Cancer Radioimmunotherapy Sales Value Growth Rate (2021-2032)
  79. 7.21.2 Argentina Cancer Radioimmunotherapy Sales Value Share by Type, 2025 VS 2032
  80. 7.21.3 Argentina Cancer Radioimmunotherapy Sales Value Share by Application, 2025 VS 2032
  81. 7.22 Chile
  82. 7.22.1 Chile Cancer Radioimmunotherapy Sales Value Growth Rate (2021-2032)
  83. 7.22.2 Chile Cancer Radioimmunotherapy Sales Value Share by Type, 2025 VS 2032
  84. 7.22.3 Chile Cancer Radioimmunotherapy Sales Value Share by Application, 2025 VS 2032
  85. 7.23 Colombia
  86. 7.23.1 Colombia Cancer Radioimmunotherapy Sales Value Growth Rate (2021-2032)
  87. 7.23.2 Colombia Cancer Radioimmunotherapy Sales Value Share by Type, 2025 VS 2032
  88. 7.23.3 Colombia Cancer Radioimmunotherapy Sales Value Share by Application, 2025 VS 2032
  89. 7.24 Peru
  90. 7.24.1 Peru Cancer Radioimmunotherapy Sales Value Growth Rate (2021-2032)
  91. 7.24.2 Peru Cancer Radioimmunotherapy Sales Value Share by Type, 2025 VS 2032
  92. 7.24.3 Peru Cancer Radioimmunotherapy Sales Value Share by Application, 2025 VS 2032
  93. 7.25 Saudi Arabia
  94. 7.25.1 Saudi Arabia Cancer Radioimmunotherapy Sales Value Growth Rate (2021-2032)
  95. 7.25.2 Saudi Arabia Cancer Radioimmunotherapy Sales Value Share by Type, 2025 VS 2032
  96. 7.25.3 Saudi Arabia Cancer Radioimmunotherapy Sales Value Share by Application, 2025 VS 2032
  97. 7.26 Israel
  98. 7.26.1 Israel Cancer Radioimmunotherapy Sales Value Growth Rate (2021-2032)
  99. 7.26.2 Israel Cancer Radioimmunotherapy Sales Value Share by Type, 2025 VS 2032
  100. 7.26.3 Israel Cancer Radioimmunotherapy Sales Value Share by Application, 2025 VS 2032
  101. 7.27 UAE
  102. 7.27.1 UAE Cancer Radioimmunotherapy Sales Value Growth Rate (2021-2032)
  103. 7.27.2 UAE Cancer Radioimmunotherapy Sales Value Share by Type, 2025 VS 2032
  104. 7.27.3 UAE Cancer Radioimmunotherapy Sales Value Share by Application, 2025 VS 2032
  105. 7.28 Turkey
  106. 7.28.1 Turkey Cancer Radioimmunotherapy Sales Value Growth Rate (2021-2032)
  107. 7.28.2 Turkey Cancer Radioimmunotherapy Sales Value Share by Type, 2025 VS 2032
  108. 7.28.3 Turkey Cancer Radioimmunotherapy Sales Value Share by Application, 2025 VS 2032
  109. 7.29 Iran
  110. 7.29.1 Iran Cancer Radioimmunotherapy Sales Value Growth Rate (2021-2032)
  111. 7.29.2 Iran Cancer Radioimmunotherapy Sales Value Share by Type, 2025 VS 2032
  112. 7.29.3 Iran Cancer Radioimmunotherapy Sales Value Share by Application, 2025 VS 2032
  113. 7.30 Egypt
  114. 7.30.1 Egypt Cancer Radioimmunotherapy Sales Value Growth Rate (2021-2032)
  115. 7.30.2 Egypt Cancer Radioimmunotherapy Sales Value Share by Type, 2025 VS 2032
  116. 7.30.3 Egypt Cancer Radioimmunotherapy Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Novartis
  2. 8.1.1 Novartis Company Information
  3. 8.1.2 Novartis Business Overview
  4. 8.1.3 Novartis Cancer Radioimmunotherapy Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Novartis Cancer Radioimmunotherapy Product Portfolio
  6. 8.1.5 Novartis Recent Developments
  7. 8.2 Bayer
  8. 8.2.1 Bayer Company Information
  9. 8.2.2 Bayer Business Overview
  10. 8.2.3 Bayer Cancer Radioimmunotherapy Revenue and Gross Margin (2021-2026)
  11. 8.2.4 Bayer Cancer Radioimmunotherapy Product Portfolio
  12. 8.2.5 Bayer Recent Developments
  13. 8.3 Y-mAbs Therapeutics
  14. 8.3.1 Y-mAbs Therapeutics Company Information
  15. 8.3.2 Y-mAbs Therapeutics Business Overview
  16. 8.3.3 Y-mAbs Therapeutics Cancer Radioimmunotherapy Revenue and Gross Margin (2021-2026)
  17. 8.3.4 Y-mAbs Therapeutics Cancer Radioimmunotherapy Product Portfolio
  18. 8.3.5 Y-mAbs Therapeutics Recent Developments
  19. 8.4 Telix Pharmaceuticals
  20. 8.4.1 Telix Pharmaceuticals Company Information
  21. 8.4.2 Telix Pharmaceuticals Business Overview
  22. 8.4.3 Telix Pharmaceuticals Cancer Radioimmunotherapy Revenue and Gross Margin (2021-2026)
  23. 8.4.4 Telix Pharmaceuticals Cancer Radioimmunotherapy Product Portfolio
  24. 8.4.5 Telix Pharmaceuticals Recent Developments
  25. 8.5 RadioMedix
  26. 8.5.1 RadioMedix Company Information
  27. 8.5.2 RadioMedix Business Overview
  28. 8.5.3 RadioMedix Cancer Radioimmunotherapy Revenue and Gross Margin (2021-2026)
  29. 8.5.4 RadioMedix Cancer Radioimmunotherapy Product Portfolio
  30. 8.5.5 RadioMedix Recent Developments
  31. 8.6 Philogen
  32. 8.6.1 Philogen Company Information
  33. 8.6.2 Philogen Business Overview
  34. 8.6.3 Philogen Cancer Radioimmunotherapy Revenue and Gross Margin (2021-2026)
  35. 8.6.4 Philogen Cancer Radioimmunotherapy Product Portfolio
  36. 8.6.5 Philogen Recent Developments
  37. 8.7 Orano Med
  38. 8.7.1 Orano Med Company Information
  39. 8.7.2 Orano Med Business Overview
  40. 8.7.3 Orano Med Cancer Radioimmunotherapy Revenue and Gross Margin (2021-2026)
  41. 8.7.4 Orano Med Cancer Radioimmunotherapy Product Portfolio
  42. 8.7.5 Orano Med Recent Developments
  43. 8.8 Nordic Nanovector
  44. 8.8.1 Nordic Nanovector Company Information
  45. 8.8.2 Nordic Nanovector Business Overview
  46. 8.8.3 Nordic Nanovector Cancer Radioimmunotherapy Revenue and Gross Margin (2021-2026)
  47. 8.8.4 Nordic Nanovector Cancer Radioimmunotherapy Product Portfolio
  48. 8.8.5 Nordic Nanovector Recent Developments
  49. 8.9 Mundipharma
  50. 8.9.1 Mundipharma Company Information
  51. 8.9.2 Mundipharma Business Overview
  52. 8.9.3 Mundipharma Cancer Radioimmunotherapy Revenue and Gross Margin (2021-2026)
  53. 8.9.4 Mundipharma Cancer Radioimmunotherapy Product Portfolio
  54. 8.9.5 Mundipharma Recent Developments
  55. 8.10 Lantheus
  56. 8.10.1 Lantheus Company Information
  57. 8.10.2 Lantheus Business Overview
  58. 8.10.3 Lantheus Cancer Radioimmunotherapy Revenue and Gross Margin (2021-2026)
  59. 8.10.4 Lantheus Cancer Radioimmunotherapy Product Portfolio
  60. 8.10.5 Lantheus Recent Developments
  61. 8.11 Gilead Sciences
  62. 8.11.1 Gilead Sciences Company Information
  63. 8.11.2 Gilead Sciences Business Overview
  64. 8.11.3 Gilead Sciences Cancer Radioimmunotherapy Revenue and Gross Margin (2021-2026)
  65. 8.11.4 Gilead Sciences Cancer Radioimmunotherapy Product Portfolio
  66. 8.11.5 Gilead Sciences Recent Developments
  67. 8.12 Fusion Pharmaceuticals
  68. 8.12.1 Fusion Pharmaceuticals Company Information
  69. 8.12.2 Fusion Pharmaceuticals Business Overview
  70. 8.12.3 Fusion Pharmaceuticals Cancer Radioimmunotherapy Revenue and Gross Margin (2021-2026)
  71. 8.12.4 Fusion Pharmaceuticals Cancer Radioimmunotherapy Product Portfolio
  72. 8.12.5 Fusion Pharmaceuticals Recent Developments
  73. 8.13 Curium Pharmaceuticals
  74. 8.13.1 Curium Pharmaceuticals Company Information
  75. 8.13.2 Curium Pharmaceuticals Business Overview
  76. 8.13.3 Curium Pharmaceuticals Cancer Radioimmunotherapy Revenue and Gross Margin (2021-2026)
  77. 8.13.4 Curium Pharmaceuticals Cancer Radioimmunotherapy Product Portfolio
  78. 8.13.5 Curium Pharmaceuticals Recent Developments
  79. 8.14 Curasight
  80. 8.14.1 Curasight Company Information
  81. 8.14.2 Curasight Business Overview
  82. 8.14.3 Curasight Cancer Radioimmunotherapy Revenue and Gross Margin (2021-2026)
  83. 8.14.4 Curasight Cancer Radioimmunotherapy Product Portfolio
  84. 8.14.5 Curasight Recent Developments
  85. 8.15 Clarity Pharmaceuticals
  86. 8.15.1 Clarity Pharmaceuticals Company Information
  87. 8.15.2 Clarity Pharmaceuticals Business Overview
  88. 8.15.3 Clarity Pharmaceuticals Cancer Radioimmunotherapy Revenue and Gross Margin (2021-2026)
  89. 8.15.4 Clarity Pharmaceuticals Cancer Radioimmunotherapy Product Portfolio
  90. 8.15.5 Clarity Pharmaceuticals Recent Developments
  91. 8.16 China Isotope & Radiation
  92. 8.16.1 China Isotope & Radiation Company Information
  93. 8.16.2 China Isotope & Radiation Business Overview
  94. 8.16.3 China Isotope & Radiation Cancer Radioimmunotherapy Revenue and Gross Margin (2021-2026)
  95. 8.16.4 China Isotope & Radiation Cancer Radioimmunotherapy Product Portfolio
  96. 8.16.5 China Isotope & Radiation Recent Developments
  97. 8.17 Aurobindo Pharma
  98. 8.17.1 Aurobindo Pharma Company Information
  99. 8.17.2 Aurobindo Pharma Business Overview
  100. 8.17.3 Aurobindo Pharma Cancer Radioimmunotherapy Revenue and Gross Margin (2021-2026)
  101. 8.17.4 Aurobindo Pharma Cancer Radioimmunotherapy Product Portfolio
  102. 8.17.5 Aurobindo Pharma Recent Developments
  103. 8.18 Actinium Pharmaceuticals
  104. 8.18.1 Actinium Pharmaceuticals Company Information
  105. 8.18.2 Actinium Pharmaceuticals Business Overview
  106. 8.18.3 Actinium Pharmaceuticals Cancer Radioimmunotherapy Revenue and Gross Margin (2021-2026)
  107. 8.18.4 Actinium Pharmaceuticals Cancer Radioimmunotherapy Product Portfolio
  108. 8.18.5 Actinium Pharmaceuticals Recent Developments
9 Concluding Insights
    10 Appendix
    1. 10.1 Reasons for Doing This Study
    2. 10.2 Research Methodology
    3. 10.3 Research Process
    4. 10.4 Authors List of This Report
    5. 10.5 Data Source
    6. 10.5.1 Secondary Sources
    7. 10.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst